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FUS,EWS,andTAF15 formthe FET familyofRNA-binding proteins whosegenes arefoundrearranged withvarioustranscription
factor genes predominantly in sarcomasand in rare hematopoietic and epithelial cancers. The resulting fusion gene products have
attracted considerable interest as diagnostic and promising therapeutic targets. So far, oncogenic FET fusion proteins have been
regarded as strong transcription factors that aberrantly activate or repress target genes of their DNA-binding fusion partners.
However, the role of the transactivating domain in the context of the normal FET proteins is poorly deﬁned, and, therefore, our
knowledge on how FET aberrations impact on tumor biology is incomplete. Since we believe that a full understanding of aberrant
FET protein function can only arise from looking at both sides of the coin, the good and the evil, this paper summarizes evidence
for the central function of FET proteins in bridging RNA transcription, processing, transport, and DNA repair.
1.Introduction
The S t r a n g eC a s eo fD r .J e k y l la n dM r .H y d e ,an o v e lb yt h e
Scottish poet Robert Luis Stevenson (1850–1894), screened
multipletimesworldwide, describesthestruggle between the
good and evil sides of one individual [1]. At daylight, Dr.
Jekyll is an honorable member of the society, but when the
light fades he turns into an evil beast. The coexistence of two
faces of one individual has inspired more than poetry and
psychology. The question of which circumstances favor the
surfacing of one or the other and how it may be inﬂuenced
is relevant to all areas of life, including economy, technology
and medicine. Cancer unravels the “Hyde” side of genes and
their biology, but we can learn about how to tame ﬁerce Mr.
Hyde by understanding the Dr. Jekyll behind, the normal
function of cancer genes.
FET (FUS, EWS, TAF15) proteins are a ubiquitously
expressed family of similarly structured proteins predomi-
nantly localizing to the nuclear [2]. FET genes have attracted
broad attention since all known members are found involved
in deleterious genomic rearrangements with transcription
factor genes in a variety of human sarcomas and acute
leukemias.ChimericFET proteins are considered and mostly
studied as aberrant transcription factors. This paper aims at
summarizing the good sides of FET proteins and looking at
the characteristics of aberrant FET proteins as Dr. Jekyll’s
second face which surfaces only upon gene rearrangement
or mutation.
2.Dr. Jekyll
2.1. The FET Family of Proteins. The prototype FET
protein EWS was identiﬁed in 1992 as the gene prod-
uct encoded by the Ewing’s sarcoma breakpoint region
1( EWSR1) on chromosome 22q12 constituting the ﬁrst
identiﬁed member of a family of putative RNA-binding
proteins [3], including also FUS/TLS/Pigpen/hnRNP P2 [4–
7], TAF15/hTAFII68/TAF2N/RPB56 [8, 9], and Drosophila
Cabeza/SARFH[10,11]that share distinct structural charac-
teristics (Figure 1). This protein family is frequently referred
to as the FET (previously TET) (FUS/TLS, EWS, TAF15)
family of proteins. Our restricted knowledge about the
molecular functions of FET proteins derives mainly from
protein interaction studies which identiﬁed more than 30
associated proteins mostly as part ofprotein/RNAcomplexes
[12]( Table 1). Of note, pull-down experiments using EWS
as bait revealed that all three FET proteins interact with each2 Sarcoma
other and are therefore likely to be part of the very same
protein complexes. As demonstrated for EWS, the associa-
tion with most interacting proteins depends on the presence
of RNA and is destroyed upon RNaseA treatment (Table 1).
The functional roles of interacting proteins suggest a general
bridging role for FET proteins coupling RNA transcription,
processing, transport, and DNA repair.
2.2. RNA Binding of FET Proteins. Several functional FET
domains were deﬁned (see Figure 1): the N-terminal domain
is largely composed of a highly repetitive primary sequence
containing multiple copies of a degenerate hexapeptide
repeat motif similar to the C-terminal domain of RNA
polymerase II. The C-terminal domain (CTD) contains a
conserved nuclear import and retention signal (C-NLS)
[13], a putative zinc-ﬁnger domain, and a conserved RNA
recognition motif (RRM) ﬂanked by 3 arginine-glycine-
glycine (RGG) boxes [14] compatible with RNA binding
of FET proteins. FUS has been demonstrated to bind
preferentially to GGUG-containing RNAs [15]. EWS might
have similar sequence speciﬁcity since it was demonstrated
to bind strongly to both poly G and poly U, but not to poly
A and poly C RNA, homopolymers [16]. Although it is only
the zinc ﬁnger domain of FUS that makes physical contact
with the GGUG motif, all three RGG boxestogether with the
RRM contribute to this activity [15]. Intriguingly, a recent
study identiﬁed strong binding of FUS to human telomeric
RNA [17] and to small low-copy-number RNAs tethered to
the promoter of cyclin D1 [18]. Nothing is known about the
RNA binding speciﬁcity TAF15.
2.3. A Role for FET Proteins in RNA Transcription. The FET
N-terminal domain (NTD) resembles the activation domain
ofcertain transcriptionfactorssuchasSP-1rich inglutamine
and proline residues. When fused to a DNA-bindingdomain
(DBD), as is the case in oncogenic FET derivatives, the NTD
strongly activates reporter gene activity in a DNA-binding-
dependent way [19–23]. The critical determinants for this
transactivation activity are dispersed throughout the NTD
[24], which is intrinsically disordered [25]. It is comprised
of a variable number of a degenerate hexapeptide repeat
motif (DHR) with the consensus SYGQQS, with homologies
to the C-terminus of RNA polymerase II [3]. Mutation
analysis of the EWS NTD revealed a critical dependence of
the transactivation activity on the aromatic side chain of the
conserved tyrosine residue present in the DHR [21].
The function of the NTD in the context of germline
FET proteins remains largely unexplored. When included
into artiﬁcial FET-DBD fusion proteins, the CTD inhibited
transcriptional activation by theNTD [26]. More recent data
demonstrated that the RGG motifs of the FET-CTD repress
a range of transcriptional activation domains [27]. The
context-dependentdiﬀerenceinthetransactivation potential
o ft h eN T Dm i g h tb ee x p l a i n e db yd i ﬀerent structures and
accessibility of the NTD for protein interactions in the
presence and absence of the CTD [28]. Protein interaction
between the very N-terminus of EWS and the RNA PolII
holoenzyme component hsRPB7 was only observed for
EWS-FLI1 and C-terminal truncated EWS, while interac-
tion with hsRPB5 and hsRPB3 was restricted to germline
EWS [29, 30]. EWS has been reported to support CREB-
binding-protein-(CBP/p300-) dependent activation by the
transcription factors HNF-4 and OCT-4 [31, 32]w h i c hi s
inhibited by the EWS-interacting protein STRAP (serine-
threonine kinase receptor-associated protein)[33]. Similarly,
FUS acts as a positive cofactor for NFkappaB-mediated
transcription [34]. In contrast, EWS repressed BRN3A-
dependent transcription [35].
All three FET proteins were found to associate with RNA
polymerase II and subpopulations of the TFIIDc o m p l e x ,
respectively [8, 29, 36]. Consistent with an evolutionary
conservedroleofFETproteinsinRNAtranscription, SARFH
was found to be associated with transcribed chromatin
in Drosophila [10]. Interactions of the NTD with various
transcription factors were described (FUS with steroid,
thyroid hormone, and retinoid receptors [37], EWS with
Brn3A and via CBP/p300 with HNF4 and OCT4 [31, 32,
35, 38]). Interestingly, EWS and FUS were found to bind
directly to the proximal elements of the macrophage-speciﬁc
promoter of the CSF-1 receptor (CSF1R)g e n ea n da l s ot o
high-aﬃnity sitesrecognized bymyeloidzincﬁngerprotein1
(Mzf1) suggesting a role in transcriptional start site selection
of TATA-less promoters [39].
Besides their role in RNA-polymerase-II-mediated tran-
scription, the recent ﬁnding of FUS repressing RNA poly-
merase III-dependent transcription of small untranslated
RNAs implies a more general role for FET proteins in the
orchestration of the transcriptome [40].
2.4. A Role for FET Proteins in mRNA Maturation. The RNA-
binding speciﬁcity of FUS for the GGUG motif found in
5 splice sites suggests a role in RNA processing. EWS and
FUS were identiﬁed within the same RNA-splicing com-
plex together with polypyrimidine-tract-binding-protein-
associated factor (PSF) [41]. In addition, EWS and FUS
associate with a variety of splicing factors such as U1C, SR,
SF1, and YB1 [15, 42–47]. Further, EWS NTD and FUS bind
to novel RNA helicases [48, 49]. Moreover, interaction of
the EWS NTD with BARD1, a protein playing an important
role in the inhibition of RNA maturation at sites of stalled
transcription upon DNA damage, was reported [31, 50–53].
Together, these results suggest that FET proteins coupleRNA
transcription to processing. The mechanism and speciﬁcity
of this activity remain largely unknown.
2.5. A Role for FET Proteins in the Processing of Small
Noncoding RNAs. EWS was recently identiﬁed in a protein
complex with the nuclear RNase III DROSHA [54]. While
DROSHA is known to be central to the cleavage of the pre-
micro-RNA (miRNA) precursor from the primary miRNA
transcript thereby initiating miRNA processing and trans-
port to the cytoplasm, evidence for a functional role of the
EWS containing DROSHA complex is missing. Therefore,
a general role for EWS in the metabolism of noncoding
RNAs remains to be demonstrated. Since about a quarter of
miRNA genes are encoded in the introns of protein-codingSarcoma 3
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Figure 1: Structure of the prototype FET protein EWS.
genes [55], it is intriguing to speculate that EWS links not
only transcription to RNAsplicing butalso to the generation
of miRNAs from gene introns. This, so far hypothetical,
activitymay gain importance inthelightoffrequentnegative
posttranscriptional regulation of miRNA processing at the
DROSHA level in cancer [56].
2.6. A Role for FET Proteins in RNA Transport. Consistent
with their proposed function in gene regulation, FET
proteins are mostly nuclear, localizing to inclusions such as
the coiled body and the nucleolus (demonstrated for EWS,
FUS, and pigpen in [9, 57, 58]). There is also evidence that
FET proteins shuttle between the nucleus and the cytoplasm
raising the possibility that they play a role in RNA transport
[59, 60]. In mouse hippocampal neurons, FUS is localized
to neuronal dendrites and, upon activation, translocate to
the spines, where local translation takes place, carrying along
speciﬁc mRNA transcripts [61, 62]. This ﬁnding implicates
FET proteins in localizing cytoplasmic determinants for the
local control of protein synthesis and secretion, at least in
neurons.
For EWS, RNA binding, subcellular localization, and
consequently transcriptional activity have been found to be
regulated by extensive asymmetric dimethylation of theRGG
motifs, mediated by protein arginine methyltransferases 1
and 8 (PRMT1, PRMT8) [67–70], which likely impacts
on self-association of intact EWS required for nuclear
localization [71, 72]. Extensively methylated EWS has even
been identiﬁed on the cell surface [73]. So far, the functional
relevance of these ﬁndings has yet to be determined.
2.7. A Role for FET Proteins in Genome Surveillance and
DNA Repair. FUS deﬁciency in mice resulted in defective
B-lymphocyte development and activation, high levels of
chromosomal instability, and perinatal death [74]. EWS
knock-out mice also displayed disrupted B-cell development
and were extremely sensitive to ionizing radiation. Together
with a defect in homologous recombination impairing
meiosis and the observation of premature senescence of
embryonic ﬁbroblasts, these results suggest a role for EWS in
recombination repair [75]. In the zebraﬁsh, silencing of EWS
genes during embryogenesis led to mitotic defects followed
by p53-dependent apoptosis [76].
Consistent with the phenotype of FET deﬁciency in
geneticallymodiﬁed mice,theinteractionofEWS(andEWS-
FLI1) with the BRCA1-associated ring ﬁnger domain protein
BARD1 may point to a role of FET proteins in DNA double-
strand break repair [53]. This hypothesis is strengthened
by high genomic instability in FUS knock-out mice [74]
and radiation sensitivity and impaired homologous recom-
bination in EWS knockouts [75]. The recently discovered
homologous DNA-strand-pairing activity of all four FET
proteins may functionally contribute to this role [77].
Intriguingly, the RNA binding activity of FUS was
reportedtoactasasensorforDNAdamageandtoelicittran-
scriptional repression; as exempliﬁed for cyclin D (CCND1)
promoter regulation, DNA damage was demonstrated to
induce the expression of single-stranded, low-copy-number
ncRNA transcripts tethered to the 5  regulatory regions of
CCND1 which recruit FUS and allosterically modify it to
bind to and repress CREB-binding protein (CBP) and p300
histone acetyltransferase activities [18].
Activation of gene transcription by many, if not all,
sequence-speciﬁc transcription factors requires DNA-
topoisomerase-II-beta-dependent, transient, site-speciﬁc
dsDNA break formation [78] .O n em a ys p e c u l a t et h a tt h e
proposed role of FET proteins in recombination repair
is linked to their association with transcription initiation
complexes at promoter regions.4 Sarcoma
Table 1: EWS interacting proteins: ∗not bound by methylated EWS; ∗∗not bound by methylated EWS upon RNaseA treatment.
RNase A sensitive
hnRNP A0 [12] Pre-mRNA processing, RNA metabolism, RNA transport
hnRNP A1 [12] Pre-mRNA processing, RNA metabolism, and RNA transport may modulate splice
site selection
hnRNP A2B1 [12] Pre-mRNA processing, RNA metabolism, RNA transport
hnRNP A3 [12] Regulation of age-related gene expression, binds to telomeric RNA
hnRNP A/B [12] Binds to multiprotein editosome complex
hnRNP A18∗ [12] Stabilization of transcripts, genotoxic stress response, translationalactivator, binds
to 3 UTR
hnRNP D0 [12] Regulation of mRNA stability
hnRNP F [12] Binds G-rich sequences
hnRNP G [12] Regulation of splice site selection, DNA double-strand break repair
hnRNP H [12] Pre-mRNA alternative splicing regulation
hnRNP H2 [12] Involved in Fabray disease and X-linked agammaglobulinemia
hnRNP H3 [12] Early heat shock-induced splicing arrest
hnRNP Q [12] RNA stability, translationallycoupled mRNA turnover
Small nuclear ribonucleoprotein Sm D3 [12] Pre-mRNA splicing and small nuclear ribonucleoprotein biogenesis, histone 3 -end
processing
U1 small nuclear ribonucleoprotein A∗ [12] First snRNP to interact with pre-mRNA for the subsequent binding of U2 snRNP
and the U4/U6/U5 tri-snRNP
Splicing factor, arginine/serine-rich 1∗ [12, 44] Accuracy of splicing and regulation of alternative splicing
Splicing factor, arginine/serine-rich 3∗ [12] Putative proliferation-/maturation-associatedRNA processing
Splicing factor, arginine/serine-rich 9∗ [12] Constitutive splicing
RRM containing coactivator activator [12] Activation/modulation of nuclear receptors
Tubulin alpha ubiquitous chain [12] Scaﬀold for cell shape and organelle movement
Vimentin1 Organizer of a number of critical proteins involved in attachment, migration,and
cell signaling
RNase insensitive
Protein arginine N methyltransferase 1 [12] Epigenetic regulation, signal transduction, DNA repair
Protein arginine N-methyltransferase 8 [63] Localized at cell membrane
hnRNP M [12] Splicing, selective recycling of immature GlcNAc-bearing, thyroglobulin molecules,
potentially involved in signalling
hnRNP U [12, 43] Binds double- and single-stranded RNA and DNA, binds pre-mRNA
FUS∗∗ [12] This review
TAF15∗ [12] This review
EWS∗ [64] This review
RNA-dependent helicase p68 (DDX5) [12] RNA-dependent ATPase, alteration of RNA secondary structure in splicing and
translationinitiation
RNA-dependent helicase p72 (DDX17) [12] RNA-dependent ATPase, alteration of RNA secondary structure in splicing, and
translationinitiation
ATP-dependent RNA helicase A [12] ATP-dependent unwinding of double-stranded RNA and DNA-RNA complexes,
transcriptional regulation
ATP-dependent RNA helicase DHX36∗ [12] Deadenylation and decay of mRNAs with 3 -UTR AU-rich elements
Elongation factor EF1 gamma [12] Translationelongation, role in anchoring the translational complex to other cellular
components
Elongation factor EF1 alpha [12] Translation elongation, promotes aminoacyl-tRNA binding to ribosome
Dead box protein 3 X (DDX3X)∗ [12] ATP-dependent RNA helicase
Tubuline beta-2 chain [12] Scaﬀold for cell shape and organelle movement
RNA dependence unknown:
RBP3 [29] RNA PolymeraseII component
TAF5 [29] General transcription factor TFIID component
TAF7 [29] General transcription factor TFIID componentSarcoma 5
Table 1: Continued.
RNase A sensitive
TAF11 [29] General transcription factor TFIID component
TAF13 [29] General transcription factor TFIID component
Brn-3a [35] Transcription factor
SF1 [47] Splicing factor
YB1 [42] Splicing factor
Survival motor neuron protein∗ [65] Essential role in spliceosomalsnRNP assembly in the cytoplasm and is required for
pre-mRNA splicing in the nucleus
Serine threonine kinase receptor (STRAP) [33] Inhibits transforming growth factor beta (TGF-beta) signaling
BARD1 [53] DNA repair, mRNA maturation
Pyk2 [66] Tyrosine kinase, signaltransduction
3.Mr. Hyde
3.1. The Role of FUS in Neurodegenerative Disease. Point
mutations of FUS have recently been found in a subset of
patients with familial amyotrophic lateral sclerosis (ALS),
a neurodegenerative disorder destroying motoneurons [79,
80]. Previously, this disease has been associated with muta-
tions in either superoxide dismutase 1 (SOD1) or TDP43
(43kDa TAR DNA-binding domain protein). TDP43 is
an essential nuclear RNA-binding protein that participates
in transcriptional repression, exon splicing inhibition, and
mRNA stabilization. The convergent phenotypes associated
with FUS and TDP43 mutations suggest that they are part
of the same machinery. In fact, TDP-43 and FUS were
demonstrated to function in a biochemical complex to
modulate expression of HDAC6, a recently identiﬁed mRNA
substrate of TDP-43 [81].
3.2. The Oncogenic Function of FET Fusion Protein. The
predominant type of FET g e n ea b e r r a t i o n si st h a to ff u s i o n s
to various transcription factor genes by which the FET RNA-
binding domain is replaced by the DNA-binding domain of
the transcription factor (Table 2). FET fusion proteins are
capable of transforming cells in culture dependent on the
cellular context. EWS-ETS fusions, for example, transform
NIH3T3 and bone-marrow-derived mesenchymal progeni-
tor cells, but not human or rat primary ﬁbroblasts, mouse
embryonic stem cells, or embryonic ﬁbroblasts [102, 103].
Thephenotypeoftumorsobtainedinimmunodeﬁcientmice
aftertransplantation ofEWS-ETS-transformedNIH3T3cells
clearly diﬀers from that obtained after transformation with
other EWS-transcription factor fusions and resembles that
of Ewing’s sarcoma [104, 105]. In the xenograft model,
the amino terminal portion of EWS, as well as FUS (and
presumably also TAF15), is functionally interchangeable in
the fusion protein, while the transcription factor moiety
determines the tumor phenotype [7]. Functional inter-
changeability of the FET-NTD is also reﬂected in human
sarcomas: both EWS-CHOP and FUS-CHOP characterize
myxoid liposarcoma [5, 94], and EWS-NR4A3 and TAF15-
NR4A3 are found in extraskeletal myxoid chondrosarcoma
[106]. It was therefore hypothesized that FET fusion pro-
teins aﬀect diﬀerentiation programs by aberrant regulation
of genes speciﬁcally recognized by the transcription factor
DNA-binding moiety.
The best studied example in this respect is EWS-
FLI1 in Ewing’s sarcoma family tumors (ESFT). Using
experimental knockdown of EWS-FLI1 in ESFT cell lines
and comparison to primary tumours and normal tissues,
signatures of the chimeric transcription factor on the ESFT
transcriptome were deﬁned [125, 130, 131]. An almost equal
number of genes were found activated and repressed by
EWS-FLI1. Of the approximately 600 to 800 signiﬁcantly
dysregulated genes, only a fraction is directly bound by
EWS-FLI1 and many EWS-FLI1 bound genes do not show
aberrant regulation (our unpublished observations). Over
the years a number of directly EWS-FLI1-regulated genes
have been characterized in ESFT (Table 3). It is interesting
to note that almost all attempts to experimentally restore
the presumed “normal” expression pattern of these targets
in ESFT cell lines (by ectopic reexpression of EWS-FLI1
repressed genes and knockdown of EWS-FLI1-activated
genes) resulted in reduced tumor cell growth in vitro
and/or reduced tumorigenicity in vivo and in several cases
enhanced chemosensitivity (Table 3). These results suggest
thatdirectlyEWS-FLI1-regulatedgenesplayessential rolesin
the establishment and/or the maintenance of the malignant
phenotype of ESFT.
Functional annotation of EWS-FLI1-regulated genes re-
vealed that activated genes primarily annotate to prolifer-
ation-associated functions, while genes involved in devel-
opmental and diﬀerentiation processes are predominantly
repressed [131], suggesting that EWS-FLI1 suppresses dif-
ferentiation of the enigmatic ESFT precursor cell. In fact,
sustained silencing of EWS-FLI1 restores the potential of
ESFT cells to diﬀerentiate along adipogenic, neuronal, and
osteogeniclineages[132],afeaturesharedwithmesenchymal
stem cells (MSC). Conversely, ectopic EWS-FLI1 expression
blocks the diﬀerentiation potential of MSC and imposes an
ESFT-like phenotype on them [103, 133, 134]. Consistent
with the role of EWS-FLI1 in the disruption of develop-
mental diﬀerentiation processes is the ﬁnding of skeletal
malformations in mice expressing transgenic EWS-FLI1
in the mesenchymal lineage [135]. Similarly, the FUS-
ERG fusion found in human myeloid leukemia with the
t(16;21) translocation was demonstrated to block terminal6 Sarcoma
Table 2: FET gene fusions in cancer. TF: transcription factor.
Phenotype FET partner TF partner TF type Ref.
ESFT
(85%) EWS FLI1 ETS [3]
(10%) EWS ERG ETS [82, 83]
(1%) EWS ETV1 ETS [84]
(1%) EWS ETV4 ETS [85, 86]
(1%) EWS FEV ETS [87]
(1%) FUS FEV ETS [25]
(1%) FUS ERG ETS [88]
ESFT-like EWS NFATC2 rel related [89]
Askin-like, CD99 neg. EWS ZNF278 zinc ﬁnger [90]
Bone sarcoma EWS POU5F1 pou [91]
Mucoepidermoid carcinaoma EWS POU5F1 pou [92]
Hidradenoma EWS POU5F1 pou [92]
EWS PBX1 homeobox [92]
Low-grade ﬁbromyxoid sarcoma FUS CREB3L1 Leucine zipper [93]
Myxoid liposarcoma EWS DDIT3 bZIP [94]
FUS DDIT3 bZIP [5]
Clear cell sarcoma EWS ATF1 bZIP [95]
EWS CREB1 bZIP [96]
Desmoplastic SRCT EWS WT1 zinc ﬁnger [97]
Extraskeletal myxoid chondrosarcoma EWS NR4A3 nuclear receptor [98]
TAF15 NR4A3 nuclear receptor [99]
AML FUS ERG ETS [100]
cALL, AUL EWS ZNF384 zinc ﬁnger [101]
AML, ALL TAF15 TAF15 zinc ﬁnger [101]
diﬀerentiation of and confer a growth advantage to human
myeloid progenitor cells [136].
Consistent with early in vitro data [19–21], acti-
vated genes showed an enrichment of ETS-binding motifs
in their promoters while this motif was underrepresented
in repressed genes [131]. This result suggests that gene re-
pression regulating diﬀerentiation genes might be mediated
by indirect mechanisms. One such mechanism involved
in blocking osteogenic diﬀerentiation is interaction and
interference of EWS-FLI1 with the master regulator of bone
and cartilage development, RUNX2 [137]. RUNX2 was
demonstrated to bind also to intact EWS and FUS [138].
An u m b e ro fd i ﬀerent transcription factor binding motifs
overrepresented in the promoters of EWS-FLI1-repressed
genes may be indicative of other protein interactions that
remain to be deﬁned. Additional mechanisms of gene
repression downstream of EWS-FLI1 involve the activity of
transcriptional repressors whose expression is upregulated
by EWS-FLI1 such as NKX2.2 [139] or the epigenetic
modiﬁer EZH2 [120] and the regulation of microRNAs
[140]. An alternative intriguing mechanism may involve the
binding of EWS-FLI1 to microsatellites outside of promoter
regions even at distances of several megabases from the
transcriptional start sites [141–143]. While these elements
can activate transcription when juxtaposed to a promoter,
their activity and mechanism of action from distant sites
remains elusive.
Interestingly, there is evidence that EWS and EWS-FLI1
form a fatal liaison in that genes targeted by the FLI1 DNA-
binding domain encode for proteins that interact with the
EWS N-terminal domain in both the intact EWS protein
and the chimeric protein. This is the case for NR0B1,
a protein known to form large complexes with the stem
cell factors OCT3 and OCT4, as well as EWS [32, 144,
145]. Intriguingly, the translocation t(6;22)(p21;q12) found
in some undiﬀerentiated sarcomas and neoplasms of skin
and salivary glands directly fuses OCT4 to EWSR1.A m o n g
EWS-FLI1-repressed genes is also hsa-mir-145, a microRNA
targeting OCT4 and other stem cell factors and feeding
back on EWS-FLI1 expression [133]. These ﬁndings provide
evidencethat EWSand EWS-FLI1form a functional network
in the regulation of tumor cell stemness.
3.3. A Transcription-Independent Role for the EWS-FLI1
Fusion Protein. The ﬁrst indication that malignant trans-
formation by FET fusion proteins may involve functions
other than direct transcriptional activation of target genes
recognized by the DBD came from functional dissection
of the EWS-FLI1 fusion protein in NIH3T3 transformation
assays. These studies suggested that the minimal transform-
ing and the minimal transcriptional activation domains can
be separated from each other [146]. Speciﬁcally, the 83 N-
terminal amino acids were suﬃcient to transform NIH3T3Sarcoma 7
Table 3: Validated direct EWS-FLI1 target genes.
EWS-FLI1
activated genes Consequences of target suppression
Id2 [107] Not known
GLI1 [108] Reduced anchorage independent growth [109]
VEGF [110] Decreased osteolysis [111]
STYXL1 [112]N o t k n o w n
PLD2 [113] Inhibition of PDGF BB signalling
PTPL1 [114] Reduced growth and increased
chemosensitivity [114]
CAV1 [115] Reduced anchorage independent growth,
reduced tumorigenicity
GSTM4 [116] Abrogation of oncogenic transformation,
increased chemosensitivity [116]
NR0B1
[117, 118] Abrogation of oncogenic transformation[119]
EZH2 [120] Reduced anchorage independent growth,
reduced tumorigenicity [120]
AURKA,
AURKB [121] Not known
Tenascin C [122]N o t k n o w n
EWS-FLI1
repressed genes Consequences of target restoration
TGFBR2 [123] Loss of tumorigenicity [123]
CDKN1A [124] Inhibition of cell growth [124]
IGFBP3 [125] Inhibition of cell growth and motility [126]
FOXO1 [127]N o t k n o w n
DKK1
[128, 129] Decreased tumorigenicity [128]
cells when fused to the FLI1 DBD. Protein interactions with
this domain were found to be context dependent [28–30].
In addition, residual transforming activity of EWS-FLI1 was
retained evenwhen the FLI1-DBD was destroyed, suggesting
a DNA-binding-independent function for the oncogenic
fusion protein [147, 148]. Also, EWS-FLI1 was shown to
inhibit the CBP-dependent transcriptional activity of the
retinoid acid (RA) receptor RXR desensitizing cells to the
diﬀerentiation and apoptosis inducing activity of RA by a
mechanism unrelated to DNA binding [38].
Protein interaction studies revealed that the EWS-NTD
and the FUS-NTD in the context of their oncogenic fusion
proteinscommunicatewith thesame RNAprocessing factors
as in germline EWS [42–44, 46, 47, 53] but interfere with
serine arginine protein (SR) and YB1-mediated splicing
[42, 44, 45]. In addition, it was demonstrated that EWS-
FLI1, but not EWS, interfered with heterogeneous nuclear
ribonucleoproteinA1-dependent5  splice site selection in an
in vivo E1A splicing assay [149]. This result might possibly
be explained by a dominant negative eﬀect of EWS-FLI1
on the RNA processing function of EWS that remains to
be investigated. In fact, we have previously demonstrated
that EWS-FLI1 can interact with its germline counterpart
[64]. Importantly, mutational analysis of EWS-FLI1 revealed
that the ability to aﬀect pre-mRNA splicing coincided with
transforming activity [149]. These results suggest a role for
EWS-FLI1 in RNA processing. However, this role may not
be regarded as transcription independent. A recent study
of transcriptional elongation of the direct EWS-FLI1 target
gene cyclin D1 (CCND1) revealed that both EWS and EWS-
FLI1 stimulate transcription of the gene, but elongation by
EWS-FLI1 is signiﬁcantly slowed down in comparison to
EWS. As a result, expression of the oncogenic splice isoform
D1b is favoured over the splice isoform D1a [150]. So far it
remains unknown how many genes may be aﬀected by this
or a similar phenomenon.
3.4.EWS-FLI1and DisruptedTumorSuppression. FETfusion
proteins are aberrantly expressed transcription factors driv-
ing cell proliferation. As such they impose oncogenic stress
on the cell triggering the p53 checkpoint [151]. ESFT escape
the oncogenic stress imposed by EWS-FLI1 by modulating
p53 activity. Two mechanisms for this oncogenic property
of EWS-FLI1 have recently been described: interference
with tumor suppressive NOTCH signalling pathway activity
through transcriptional regulation of autocrine NOTCH lig-
and expression [152] and direct interaction with p53 [153].
It should be noted, however, that the ability of EWS-FLI1
to modulate p53 activity is tissue dependent. In ﬁbroblasts,
EWS-FLI1 was demonstrated to elicit a p53-mediated cell-
cycle arrest [151]. Most other cell types do not tolerate
EWS-FLI1 expression at all and die in response to ectopic
expression of the chimeric oncogene (for review [102]). The
only tissue permissive to the oncogenic properties of EWS-
FLI1 identiﬁed so far is mesenchymal stem cells [103]. The
tissue-speciﬁc factors that steer the p53 response into the
one (growth arrest/apoptosis) or the other (escape from
oncogenic stress) direction remain to be elucidated.
There is also evidence for EWS-FLI1 interfering with
the other central tumor suppressor pathway in oncogen-
esis: although the mechanisms t i l lr e m a i n st ob ed e ﬁ n e d ,
knockdown of EWS-FLI1 in ESFT cells leads to pRB-1
hypophosphorylation [154].
4.GettingHold ofMr. Hyde
The development of small molecule inhibitors of biological
macromolecules, originally in the context of chromosome
translocations, has been pioneered by research on receptor
tyrosine kinases. Here, the design of smart molecules is
guided primarily by crystallography and structure/function
analyses of the target proteins. For FET fusion proteins, this
approach is not feasible because of the intrinsic disorder of
their structure. However, recent landmark studies provided
proof of principle for successful interference with pro-
tein interactions of intrinsically disordered proteins [155].
Guided by a peptide aptamer screen, a small molecule
mimetic was described that competes with RNA helicase A
for interaction with the EWS N-terminus in the context of
the EWS-FLI1 fusion protein and slowed tumor formation
in mice [156]. There is evidence from protein interaction
studies that the faces of the EWS N-terminus look diﬀerent
in the context of the wildtype protein (Dr. Jekyll) and the8 Sarcoma
transcription factor fusion protein (Mr. Hyde) [28–30].
Thus, there is hope that the evil culprit for the development
andprogressionofseveralsarcomasandleukemiasthatisstill
hiding in the dark can be successfully targeted in the near
future.
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